Dermatologic Disorders

Resource Center

Resources
Research Summaries FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As
Interactive
Polls Quizzes
An Atlas of Lumps and Bumps
Photo Essay

FDA Alerts

FDA Approval
woman showing doctor her arm
FDA Approval
Icotyde (icotrokinra) Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis
03/19/2026
Anthony Calabro, MA
The FDA has approved icotrokinra, an oral interleukin-23 receptor antagonist, for patients aged 12 years and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or...
03/19/2026
FDA Alert
ointment
FDA Alert
Topical Treatment for Molluscum Contagiosum in Adults, Children Approved by FDA
07/26/2023
Jessica Ganga
Following two trials, the FDA has approved the first treatment for molluscum contagiosum.
07/26/2023
treatment
treatment
FDA Approves First Alopecia Areata Treatment
06/22/2022
The US Food and Drug Administration has approved the first systemic treatment for alopecia areata following the publication of results from 2 randomized, placebo-controlled trials.
06/22/2022
skin cancer
skin cancer
FDA Approves Metastatic, Unresectable Melanoma Treatment
04/21/2022
The US Food and Drug Administration has approved a new medication therapy for the treatment of metastatic and unresectable melanoma.
04/21/2022
Lice infestation
Lice infestation
FDA Approves OTC Lotion to Treat Head Lice
10/28/2020
A prescription is no longer needed to obtain the topical lotion for treating head lice. This comes in response to the millions of cases of head lice reported annually by the Centers for Disease Control and...
10/28/2020
Dermatologic Disorders
Dermatologic Disorders
FDA Warning: Olanzapine Can Cause Serious Skin Reactions
05/12/2016
The FDA has warned that the antipsychotic drug, olanzapine, may be associated with a rare but serious skin reaction.
05/12/2016
FDA ALERT
fda
FDA ALERT
FDA Approves Interchangeable Biosimilar for Psoriatic Arthritis, Other Inflammatory Conditions
11/08/2015
Anthony Calabro, MA
The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.
11/08/2015
FDA ALERT
FDA ALERT
FDA Approves Interchangeable Biosimilar for Psoriatic Arthritis, Other Inflammatory Conditions
11/08/2015
Anthony Calabro, MA
The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.
11/08/2015
Dermatology
Dermatology
FDA: First Treatment for Hidradenitis Suppurativa Approved, SGLT2 Inhibitor Fracture Warnings Strengthened
09/11/2015
The FDA has approved new options for hidradenitis suppurativa and hereditary orotic acuduria.
09/11/2015
Skin Cancer
Skin Cancer
FDA Approves First PCSK9 Inhibitor, New Drug for Basal Cell Carcinoma, and More
07/27/2015
The FDA has approved new options for basal cell carcinoma, HIV diagnosis, and high cholesterol that clinicians should be aware of.
07/27/2015